Ilya Gipp, MD, PhD, presented “Transforming Prostate Cancer Care – The Emerging Role of Radio-Ligand Therapies” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Gipp, Ilya. “Transforming Prostate Cancer Care – The Emerging Role of Radio-Ligand Therapies.” October 8, 2024. Accessed Apr 2026. https://grandroundsinurology.com/transforming-prostate-cancer-care-the-emerging-role-of-radio-ligand-therapies/
Transforming Prostate Cancer Care – The Emerging Role of Radio-Ligand Therapies – Summary
In this 19-minute talk, Ilya Gipp, MD, PhD, a Chief Medical Officer at GE Healthcare specializing in oncology, explores the transformative potential of radioligand therapies in prostate cancer care. Highlighting the role of prostate-specific membrane antigen (PSMA), he discusses its diagnostic and prognostic significance.
Dr. Gipp introduces PET/CT imaging with radiopharmaceutical agents, emphasizing their effectiveness in diagnosing and evaluating patients for radioligand therapy. A novel diagnostic-therapeutic pairing with isotopes like Lutetium-177 is presented, demonstrating its integration into prostate cancer treatment.
The talk also touches on the broader growth of radiopharmaceutical pipelines, extending beyond prostate cancer to other conditions like neuroendocrine tumors. Current regulatory advancements are discussed. The potential of combination therapies and alpha emitters like Actinium further highlights the dynamic research landscape.
Clinical results, including striking imaging of patient responses, underscore the efficacy of PSMA-based radioligand therapies, which show promise in improving survival rates in metastatic castration-resistant prostate cancer. Concluding with a call for continued innovation and multimodal integration, the speaker highlights radioligand therapy as a cornerstone for future advancements in personalized oncologic care.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Ilya Gipp, MD, PhD is Chief Medical Officer, Oncology at GE Healthcare in Atlanta, Georgia. Dr. Gipp leads the development and execution of the medical and clinical strategy for cancer care solutions. His focus is on the clinical, organizational, financial, and population health dimensions of breast, prostate, lung, colorectal, liver, head and neck, and other cancers. Dr. Gipp guides the clinical aspects of market strategy, product development, solution design, and implementation across GE HealthCare’s Oncology Pathways field.
